Reference health
Countermeasures for Preventing and Treating Opioid Overdose
72/72 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
15 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 72 checked references that resolve
resolves10.1007/s13181-019-00750-x
National Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)—August 6/7, 2019
resolves10.1124/jpet.118.256115
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose
resolves10.1093/bja/85.4.533
Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery†
resolves10.1002/jcph.1384
Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose
resolves10.1016/j.brainres.2005.07.060
Comparison of the antinociceptive effect of acute morphine in female and male Sprague–Dawley rats using the long-lasting mu-antagonist methocinnamox
resolves10.1124/jpet.119.260331
Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of µ-Opioid Receptor Agonists but Not Prolonged Precipitated Withdrawal in Rats
resolves10.1124/jpet.118.253286
Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys
resolves10.1124/jpet.118.252353
Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys
resolves10.1038/s41386-020-0698-8
Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys
resolves10.1007/s00213-020-05592-y
Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys
resolves10.1016/j.annemergmed.2019.04.020
One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose
resolves10.1016/j.neubiorev.2018.12.005
Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment
resolves10.1093/jat/21.2.105
Plasma Concentrations of Heroin and Morphine-Related Metabolites after Intranasal and Intramuscular Administration
resolves10.1177/2042098617744161
Naloxone dosage for opioid reversal: current evidence and clinical implications
resolves10.1002/phar.2117
The Pharmacokinetics and Pharmacodynamics of Carfentanil After Recreational Exposure: A Case Report
resolves10.1136/bmj.2.5919.589
Degree and Duration of Reversal by Naloxone of Effects of Morphine in Conscious Subjects
resolves10.1007/s00213-005-2155-0
Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal
resolves10.1016/0022-3956(92)90014-F
Nasal administration of naloxone for detection of opiate dependence
resolves10.1016/S0168-3659(02)00127-X
Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake
resolves10.1016/S0168-3659(98)00121-7
Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix
resolves10.1016/j.addr.2016.06.018
Polylactic acid (PLA) controlled delivery carriers for biomedical applications
resolves10.1016/S0168-3659(97)00147-8
Transdermal delivery of fentanyl: rapid onset of analgesia using skin electroporation
resolves10.1016/j.jconrel.2007.05.017
Ex vivo evaluation of bioadhesive films for buccal delivery of fentanyl
resolves10.1016/j.jconrel.2014.03.053
An overview of clinical and commercial impact of drug delivery systems
resolves10.1016/S0168-3659(00)00268-6
Evaluation of poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide) (PEO–PPO–PEO) gels as a release vehicle for percutaneous fentanyl
resolves10.1021/acsabm.9b00380
Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone
resolves10.1152/japplphysiol.01270.2009
The role of medullary serotonin (5-HT) neurons in respiratory control: contributions to eupneic ventilation, CO<sub>2</sub>chemoreception, and thermoregulation
resolves10.1016/S0022-3476(97)70315-9
Treatment of apneustic respiratory disturbance with a serotonin-receptor agonist
resolves10.1016/0304-3940(94)90662-9
Serotonin 1A-receptor activation suppresses respiratory apneusis in the cat
resolves10.1111/j.1469-7793.1998.245bo.x
Blockade of synaptic inhibition within the pre‐Bötzinger complex in the cat suppresses respiratory rhythm generation <i>in vivo</i>
resolves10.1016/j.resp.2016.01.007
Blockade of dorsolateral pontine 5HT1A receptors destabilizes the respiratory rhythm in C57BL6/J wild-type mice
resolves10.1097/ALN.0000000000000490
5-HT1A Receptor Agonist Befiradol Reduces Fentanyl-induced Respiratory Depression, Analgesia, and Sedation in Rats
resolves10.1213/ANE.0b013e3181eac011
Repinotan, a Selective 5-HT1A-R-Agonist, Antagonizes Morphine-Induced Ventilatory Depression in Anesthetized Rats
resolves10.2174/1568026619666190911122040
From Receptor Selectivity to Functional Selectivity: The Rise of Biased Agonism in 5-HT1A Receptor Drug Discovery
resolves10.1038/sj.clpt.6100018
The Partial 5-Hydroxytryptamine1A Receptor Agonist Buspirone does not Antagonize Morphine-induced Respiratory Depression in Humans
resolves10.1211/jpp.61.05.0017
Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats
resolves10.1021/acs.jpcb.5b12333
Solution-State Structure and Affinities of Cyclodextrin:Fentanyl Complexes by Nuclear Magnetic Resonance Spectroscopy and Molecular Dynamics Simulation
resolves10.1021/acs.jpcb.7b02914
Predicting a Drug’s Membrane Permeability: A Computational Model Validated With <i>in Vitro</i> Permeability Assay Data
resolves10.1371/journal.pone.0108250
An Efficient, Optimized Synthesis of Fentanyl and Related Analogs
resolves10.1002/mrc.3803
NMR spectroscopic investigation of inclusion complexes between cyclodextrins and the neurotoxin tetramethylenedisulfotetramine
resolves10.1016/j.ejps.2009.07.010
Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-β-cyclodextrin, not 2,6-di-O-methyl-α-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells
resolves10.1016/S0022-2275(20)32113-1
Cell cholesterol efflux: integration of old and new observations provides new insights
resolves10.1371/journal.pone.0217371
Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids
resolves10.1136/bcr.05.2010.2986
‘I saved a life’: a heroin addict's reflections on managing an overdose using ‘take home naloxone’
resolves10.1016/j.cell.2020.02.052
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
resolves10.1016/j.neuropharm.2019.06.001
Development of vaccines to treat opioid use disorders and reduce incidence of overdose
resolves10.1080/21645515.2016.1212785
Biologics to treat substance use disorders: Current status and new directions
resolves10.1371/journal.pone.0184876
Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse
resolves10.4049/jimmunol.1500385
The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse
resolves10.7326/M20-1210
When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis
resolves10.1016/j.drugalcdep.2019.02.031
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort
The 15 references without a DOI — listed, not checked
no DOI — not checkedCenters for Disease Control and Prevention (CDC).Vital statistic rapid release: Provisional drug overdose death counts<https://www.cdc.gov/nchs/nvss/vsrr/drug‐overdose‐data.htm> (2020) Accessed August 17 2020.
no DOI — not checkedMethocinnamox is a potent, long‐lasting, and selective antagonist of morphine‐mediated antinociception in the mouse: comparison with clocinnamox, β‐funaltrexamine, and β‐chlornaltrexamine
no DOI — not checkedMu antagonist and kappa agonist properties of beta‐funaltrexamine (beta‐FNA) in vivo: long‐lasting spinal analgesia in mice
no DOI — not checkedIn vivo determination of mu opioid receptor turning in rhesus monkeys after irreversible blockade with clocinnamox
no DOI — not checkedEffects of beta‐funaltrexamine in normal and morphine‐dependent monkeys: observational studies
no DOI — not checkede_1_2_13_33_1
no DOI — not checkedSlow‐sustained delivery of naloxone reduces typical naloxone‐induced precipitated opioid withdrawal effects in male morphine‐dependent mice
no DOI — not checkedReversal of morphine‐induced apnea in the anesthetized rat by drugs that activate 5‐hydroxytryptamine(1A) receptors
no DOI — not checkedAnimal models of nociception
no DOI — not checkedDrug Enforcement Administration Counterfeit Prescription Pills Containing Fentanyls: A Global Threat
no DOI — not checkedVaccination reduces fentanyl distribution to the brain and fentanyl‐induced toxicity in mice and rats: a potential role for a prophylactic vaccine against fentanyl‐induced overdose
no DOI — not checkedCombining a candidate vaccine for opioid use disorders with extended‐release naltrexone increases protection against oxycodone‐induced behavioral effects and toxicity
no DOI — not checkedFormulation and characterization of conjugate vaccines to reduce opioid use disorders suitable for pharmaceutical manufacturing and clinical evaluation
no DOI — not checkedMonoclonal antibodies counteract opioid‐induced behavioral and toxic effects in mice and rats
no DOI — not checkedCenters for Disease Control and Prevention (CDC).CDC Wonder<https://wonder.cdc.gov/> (2020). Accessed July 2 2020
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1002/cpt.2098"><img src="https://citestamp.com/citestamped/10.1002/cpt.2098/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1002/cpt.2098)